Kayne Anderson Rudnick Investment Management
FDMT icon

Kayne Anderson Rudnick Investment Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-52
Closed -$1K – 629
2022
Q1 		$1K Buy
+52
New +$817 ﹤0.01% 629

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's FDMT Position: Q2 2022 in Review

Kayne Anderson Rudnick Investment Management sold out of 4D Molecular Therapeutics (FDMT) in Q2 2022, closing a stake of 52 shares — an estimated $1K sold.

Kayne Anderson Rudnick Investment Management first reported a position in FDMT in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 89 funds tracked by Wall St. Rank hold FDMT as of Q2 2022.

  • Kayne Anderson Rudnick Investment Management reported no remaining 4D Molecular Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 52 4D Molecular Therapeutics shares in Q2 2022, an estimated $1K.
  • Kayne Anderson Rudnick Investment Management first reported a position in 4D Molecular Therapeutics in Q1 2022 and held it in 1 quarter.
  • Kayne Anderson Rudnick Investment Management's 4D Molecular Therapeutics position peaked at $1K in Q1 2022.
  • 89 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2022.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2022, filed 12 Aug 2022.